Sinofsky F E, Pasquale S A
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick 08901-1977, USA.
Am J Obstet Gynecol. 1998 Feb;178(2):300-4. doi: 10.1016/s0002-9378(98)80016-1.
This open-label, two-period, crossover study was conducted to evaluate the effect of a single 150 mg dose of fluconazole on the pharmacokinetics of ethinyl estradiol in healthy female subjects.
Ten subjects regularly taking Ortho-Novum 7/7/7 (Ortho Pharmaceutical, Raritan, N.J.) and 10 subjects regularly taking Triphasil (Wyeth-Ayerst Laboratories, Philadelphia), which contain ethinyl estradiol 35 microg and 30 microg during days 1 to 6, respectively, were randomly assigned to receive a single 150 mg dose of fluconazole 2 hours before the oral contraceptive, on pill day 6 of one of two menstrual cycles. Ethinyl estradiol serum concentrations were measured at baseline and up to 24 hours after oral contraceptive intake. No fluconazole was administered during the other menstrual cycle, which served as the control.
Mean serum concentrations of ethinyl estradiol were increased after fluconazole administration in both oral contraceptive groups. Maximum observed serum concentration and area under the concentration-time curve values were significantly (p < 0.05) greater during the fluconazole regimens (vs regimens without fluconazole) for both oral contraceptive groups and for combined values of the two oral contraceptive groups. The mean time to reach the maximum concentration was not altered by concomitant fluconazole administration.
These findings suggest that there is a potential for a clinically significant interaction between coadministration of fluconazole and ethinyl estradiol in oral contraceptives.
本开放标签、两周期、交叉研究旨在评估单次150mg剂量氟康唑对健康女性受试者中炔雌醇药代动力学的影响。
10名定期服用Ortho-Novum 7/7/7(Ortho制药公司,新泽西州拉里坦)的受试者和10名定期服用Triphasil(惠氏-艾尔斯特实验室,费城)的受试者,在两个月经周期之一的第6天口服避孕药前2小时,随机分配接受单次150mg剂量氟康唑。在基线以及口服避孕药摄入后长达24小时测量炔雌醇血清浓度。在另一个月经周期不服用氟康唑,作为对照。
在两个口服避孕药组中,服用氟康唑后炔雌醇的平均血清浓度均升高。两个口服避孕药组以及两个口服避孕药组合并值在氟康唑治疗期间(与未服用氟康唑的治疗方案相比),观察到的最大血清浓度和浓度-时间曲线下面积值显著更高(p<0.05)。同时服用氟康唑未改变达到最大浓度的平均时间。
这些发现表明,氟康唑与口服避孕药中的炔雌醇同时给药可能存在具有临床意义的相互作用。